Avadel pharmaceuticals appoints dr. jennifer gudeman as vice president of medical and clinical affairs

Dublin, ireland, dec. 07, 2020 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of dr. jennifer gudeman to the newly formed role of vice president, medical and clinical affairs, effective immediately. in this role her responsibilities will include overseeing all medical and clinical affairs activities, including the company's lead program, once-nightly ft218.
AVDL Ratings Summary
AVDL Quant Ranking